Bayesian optimal interval design with multiple toxicity constraints-Reference-Cited by-同舟云学术

Bayesian optimal interval design with multiple toxicity constraints

Published:2018-06-05 Issue:4 Volume:74 Page:1320-1330
ISSN:0006-341X
Container-title:Biometrics
language:en
Short-container-title:Biom

Author:

Lin Ruitao¹²^ORCID

Affiliation:

1. Department of BiostatisticsThe University of Texas MD Anderson Cancer CenterHoustonTexas 77030U.S.A.

2. Key Laboratory for Applied Statistics of MOENortheast Normal UniversityChangchunJilinChina

Publisher

Wiley

Subject

Applied Mathematics,General Agricultural and Biological Sciences,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine,Statistics and Probability

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/biom.12912

Reference30 articles.

1. Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial

2. Algorithm AS 206: isotonic regression in two independent variables;Bril G.;Journal of the Royal Statistical Society, Series C (Applied Statistics),1984

3. Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials

4. On the consistency of the continual reassessment method with multiple toxicity constraints

5. Dose‐finding designs using a novel quasi‐continuous endpoint for multiple toxicities

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MT-Keyboard: A Bayesian Model-Assisted Interval Design to Account for Toxicity Grades and Types for Phase I Trials;Statistics in Biopharmaceutical Research;2024-07-02

2. Statistical and practical considerations in planning and conduct of dose-optimization trials;Clinical Trials;2024-01-19

3. Isotonic Phase I Cancer Clinical Trial Design Utilizing Patient-Reported Outcomes;Statistics in Biopharmaceutical Research;2023-11-28

4. Application of the patient-reported outcomes continual reassessment method to a phase I study of radiotherapy in endometrial cancer;The International Journal of Biostatistics;2022-11-17

5. An overview of the BOIN design and its current extensions for novel early-phase oncology trials;Contemporary Clinical Trials Communications;2022-08